



Noxopharm Enhances Cash Position with R&D Rebate

Highlights

- Funds received from Australian Government Research and Development Tax Incentive scheme strengthen cash position
- Support for encouraging Chroma™ and Sofra™ R&D pipelines

Sydney, 16 November 2023: Innovative biotech company **Noxopharm Limited (ASX:NOX)** has received a \$6.052 million rebate under the Australian Government’s Research and Development Tax Incentive scheme for expenditure during FY 2023.

Noxopharm CEO Dr Gisela Mautner said: “We are rapidly advancing our Chroma™ and Sofra™ pipeline, and have made significant progress on both fronts over the past 12 months as we continue to transform the company.

“We welcome the Federal R&D rebate as it helps companies like us grow our assets, develop intellectual property, and contribute to Australia’s economy.”

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US biotech company Nyrada Inc (ASX:NYR), which focuses on drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.